BRIEF published on 05/22/2025 at 07:05, 1 year 1 month ago Relief Therapeutics obtient la désignation de maladie pédiatrique rare de la FDA pour le RLF-TD011 FDA THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Maladie Pédiatrique Rare
PRESS RELEASE published on 05/22/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
BRIEF published on 05/15/2025 at 07:05, 1 year 1 month ago Relief Therapeutics annonce l'ordre du jour de l'assemblée générale annuelle 2025 États Financiers Assemblée Générale Annuelle Réélection Du Conseil D'administration Vote Des Actionnaires Approbation De L'indemnisation
PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
BRIEF published on 04/10/2025 at 07:05, 1 year 2 months ago Relief Therapeutics annonce ses résultats financiers et ses progrès stratégiques pour 2024 Biopharmaceutique Maladies Rares THÉRAPEUTIQUE DE SECOURS Résultats Financiers 2024 Progrès Du Pipeline
PRESS RELEASE published on 04/10/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
BRIEF published on 03/06/2025 at 07:05, 1 year 3 months ago Relief Therapeutics Ends Merger Discussions with Renexxion Shareholder Value Relief Therapeutics Strategic Objectives Renexxion Merger Termination
BRIEF published on 03/06/2025 at 07:05, 1 year 3 months ago Relief Therapeutics met fin aux discussions de fusion avec Renexxion Valeur Actionnariale Objectifs Stratégiques THÉRAPEUTIQUE DE SECOURS Renexxion Fin De La Fusion
Published on 06/26/2026 at 13:00, 49 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 01:40, 12 hours 9 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 14 hours 19 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 15 hours 19 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/26/2026 at 13:32, 17 minutes ago Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 18 minutes ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 19 minutes ago AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026
Published on 06/26/2026 at 13:00, 49 minutes ago Schweizer Electronic and Ascent Circuits Plan Strategic Indo-German PCB Cooperation
Published on 06/26/2026 at 07:00, 6 hours 49 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 6 hours 49 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 19 hours 4 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 19 hours 19 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
